GNHAF - Vifor Pharma settles Injectafer patent litigation

Vifor Pharma (OTCPK:GNHAY) and its partner American Regent, a Daiichi Sankyo Group company, have reached settlement agreements with Mylan Laboratories and Sandoz that resolve the patent litigation brought in response to Abbreviated New Drug Applications seeking approval by the FDA to market a generic version of Injectafer. Under the terms of the settlements, Vifor Pharma and American Regent will grant Mylan and Sandoz, licenses to market generic ferric carboxymaltose products in the U.S. beginning 1 July 2026. Details of all settlements are confidential.

For further details see:

Vifor Pharma settles Injectafer patent litigation